• Lexaria recently announced its intention to launch new human and animal studies exploring its patented DehydraTECH(TM) technology on GLP-1 drugs for the potential treatment of diabetes
• The studies will build on what Lexaria has achieved so far since it started its diabetes-related studies in 2022
• Its DehydraTECH-CBD demonstrated an almost three-fold improvement in drug delivery into the blood in its DIAB-A22-1 diabetes study compared to the DehydraTECH-CBD formulation used in its HYPER-H21-4 hypertension study
• These studies follow Lexaria’s announcement of its intention to study weight loss and diabetes control in a human population using DehydraTECH

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its intention to launch new human and animal studies that will explore its patented DehydraTECH(TM) technology on glucagon-like peptide-1 (“GLP-1”) drugs for improved bioavailability, cost-effectiveness, tolerability, weight loss potential, management of diabetes and other health conditions. Regarded as a significant expansion for Lexaria, these studies will build on what the company has achieved so far with its DehydraTECH-processed CBD while examining the technology’s impact on GLP-1 drugs (https://ibn.fm/r18NV).

The U.S. Food and Drug Administration (“FDA”) recently approved GLP-1 drugs for type 2 diabetes and weight loss management following their demonstration of an average loss of 15% of body weight across 667 individuals in a 68-week-long study. The drug has also demonstrated that some patients experience reduced cravings for alcohol, nicotine, and opioids while taking the drugs, with other trials showing the reduced build-up of proteins amyloid and tau in the brain, both thought to be partly responsible for Alzheimer’s.

Despite their overall potential, GLP-1 drugs have many side effects, ranging from mild ones, such as nausea and vomiting, to more serious ones, such as reduced bone density and muscle loss. Some of the more severe side effects have been reported when the drugs are taken in oral form, which has prompted researchers and medical practitioners to treat patients with lower oral doses. Given the overall nature of GLP-1 drugs to have low oral bioavailability, Lexaria, through its DehydraTECH technology, looks to address that, ultimately improving the drug’s pharmacokinetic (“PK”) performance.

In the recently completed DIAB-A22-1 diabetes study, Lexaria demonstrated an almost three-fold improvement in drug delivery into the blood compared to the DehydraTECH-CBD formulation used in its HYPER-H21-4 hypertension study. With such results in this and five other human clinical studies, Lexaria has proven severally that its technology can significantly improve the PK performance of many orally administered drugs into the bloodstream. Its applications have ranged from cannabinoids, estradiol, PDE-5 Inhibitors, and certain antiviral drugs. The company is optimistic about the technology’s application, GLP-1, and its potential to improve its bioavailability.

The animal and human clinical studies on GLP-1 will be a logical progression to Lexaria’s efforts to explore DehydraTECH in the potential treatment of diabetes, which kicked off in 2022. In its pre-clinical study DIAB-A22-1, DehydraTECH-CBD has yielded a 19.9% lowered blood glucose level, a 7% lowered overall body weight sustained over eight weeks, increased locomotor activity, lowered triglyceride levels by more than 25%, and lowered blood urea nitrogen levels by 27.9%. Given its intention to study weight loss and diabetes control in a human population using DehydraTECH, as announced on August 2, 2023, the GLP-1 studies come at the opportune time, facilitating this specific objective.

Program design for the GLP-1 study has already commenced, and initial study work is set to begin as soon as possible. This ambitious step affirms Lexaria’s commitment to creating shareholder value and advancing its technology to become a leader in its segment.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN